{"product_id":"89bio-business-model-canvas","title":"89bio Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech Business Model Canvas: Pipeline, Partnerships, and GTM Blueprint for Investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDive into 89bio’s Business Model Canvas to uncover how its pipeline, partnerships, and go-to-market strategy create competitive advantage and revenue pathways. This concise, actionable blueprint is ideal for investors, strategists, and founders. Purchase the full canvas to get editable Word and Excel files with financial implications and tactical recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs and CDMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrategic collaborations with CROs and CDMOs accelerate clinical execution and scale-up for pegozafermin by providing trial operations, bioanalytics, and GMP manufacturing. These partners de-risk timelines and costs while enabling flexible capacity; the CRO\/CDMO market exceeded $70 billion in 2024, highlighting available scale. Long-term tech-transfer agreements secure quality and continuity through late-stage development and launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and KOL Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHepatology and cardiometabolic KOLs guide 89bio study design and endpoints to align with regulatory expectations and payer evidence needs. Academic sites provide access to NASH (estimated 3–6% of U.S. adults) and severe hypertriglyceridemia (\u0026gt;500 mg\/dL, ~1–2% of adults) patient cohorts for enrollment. Peer‑reviewed publications and presentations at meetings (AASLD, ACC) build credibility and demand. Advisory boards shape label‑enabling evidence and real‑world utility assessments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEarly, frequent engagement with FDA, EMA and other agencies aligns development paths and enables use of programs like FDA Priority Review (reduced review goal from 10 to 6 months) and EMA accelerated assessment (210 to 150 days). Designations such as Breakthrough and PRIME can expedite review for high unmet-need indications. Scientific advice shapes pivotal trial protocols and CMC strategy, and planned post-approval commitments (including REMS and periodic safety reports) sustain safety and efficacy monitoring.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer and HTA Stakeholders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnerships with payers and HTA bodies shape 89bio value dossiers and access strategies, leveraging NASH prevalence estimates of 5–6% of US adults and cost-effectiveness thresholds commonly cited at $100,000–$150,000 per QALY. Budget impact and cost-effectiveness models for NASH and SHTG are co-developed over 3–5 year horizons; early outcomes data feed coverage criteria and prior authorization pathways. Collaborative pilots validate real-world value and inform rollout timelines aligned with HTA review windows (eg NICE 6–9 months).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCo-developed 3–5 year budget impact models\u003c\/li\u003e\n\u003cli\u003eTargets: $100k–$150k per QALY thresholds\u003c\/li\u003e\n\u003cli\u003eUse NASH prevalence ~5–6% US adults\u003c\/li\u003e\n\u003cli\u003ePilot programs to validate real-world value and coverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-development and Commercial Allies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSelect regional and therapeutic-area partners extend field reach into markets where NAFLD\/NASH prevalence is ~25% worldwide, enabling targeted investigator networks. Co-promotion or licensing deals can fund late-stage programs, with Phase 3 NASH trials commonly costing \u0026gt;$100M. Combination-study collaborators may open broader metabolic indications tied to cardiometabolic comorbidities. Supply and distribution alliances secure manufacturing scale-up and market access.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eregional reach: leverage local KOLs and payers\u003c\/li\u003e\n\u003cli\u003efunding: licensing\/co-promotion to offset \u0026gt;$100M Phase 3 costs\u003c\/li\u003e\n\u003cli\u003eexpansion: combo studies target cardiometabolic markets\u003c\/li\u003e\n\u003cli\u003ereliability: CDMO\/distribution pacts for scale-up\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCRO\/CDMO alliances accelerate pegozafermin Phase 3 NASH trials and GMP scale-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic CRO\/CDMO alliances accelerate pegozafermin trials and GMP scale; CRO\/CDMO market \u0026gt;$70B in 2024 and Phase 3 NASH trials often \u0026gt;$100M. KOLs, academic sites and payers (NASH 5–6% US adults) shape protocols, enrollment and HTA value dossiers. Regulatory partnerships enable expedited pathways and align label‑enabling evidence with coverage needs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO\/CDMO\u003c\/td\u003e\n\u003ctd\u003eTrials\/GMP\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$70B market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKOLs\/Academic\u003c\/td\u003e\n\u003ctd\u003eEnrollment\/Evidence\u003c\/td\u003e\n\u003ctd\u003eNASH 5–6% US\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\/HTA\u003c\/td\u003e\n\u003ctd\u003eAccess models\u003c\/td\u003e\n\u003ctd\u003e$100k–$150k\/QALY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for 89bio tailored to its therapeutic biotech strategy, covering customer segments, value propositions, channels, revenue streams, key activities (R\u0026amp;D, clinical development), partnerships, resources, and cost structure. Includes competitive advantage analysis and SWOT insights for investor presentations and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable one-page canvas that condenses 89bio’s strategy, accelerates team alignment, and saves hours structuring models—ideal for boardrooms, comparisons, and rapid executive summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesigning and executing Phase 2\/3 trials for pegozafermin in NASH and SHTG is core, with trial sizes typically in the 100s to 1,000+ patient range, driven by histology and biomarker endpoints. Activities include patient recruitment, site management, data integrity, centralized histology reads and biomarker panels. Biomarker and histology readouts drive go\/no-go decisions, while continuous safety monitoring and protocol optimization reduce risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCMC and Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScale-up of the engineered FGF21 analog (BIO89-100) demands robust process development—cell line optimization, formulation, and stability studies to support multi-kilogram GMP batches. GMP production and quality systems are being established to meet regulatory and commercial standards for late-stage trials and launch. Tech transfer to 2–3 qualified CDMOs secures supply resilience and reduces single-source risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePreparation of IND\/CTA, pivotal protocols and NDA\/BLA packages is essential; FDA PDUFA target review is 10 months standard vs 6 months for Priority Review. Orphan status grants 7 years US exclusivity and Breakthrough\/Fast Track accelerate development via intensive agency interactions. Ongoing meetings reduce approval uncertainty and label negotiations must align pivotal endpoints with payer coverage needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Affairs and Evidence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedical education, KOL engagement, and strong congress presence (NASDAQ: 89bio) build scientific standing and clinician trust; HEOR teams generate value dossiers to support payer access. Real-world studies and registries complement pivotal trials to strengthen safety and utilization data. Publications target hepatologists and cardiologists to expand awareness.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKOL engagement: targeted investigator networks\u003c\/li\u003e\n\u003cli\u003eHEOR: payer dossiers and economic models\u003c\/li\u003e\n\u003cli\u003eRWE: registries complementing trials\u003c\/li\u003e\n\u003cli\u003ePublications: peer-reviewed outreach to hepatology\/cardiology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Access and Launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMarket access and launch planning for 89bio begins pre-approval with pricing, reimbursement and distribution strategies aligned to payer dossiers and formulary timelines; field force design focuses on top specialty prescribers to maximize early uptake. Patient services and hub models smooth initiation and adherence, while supply chain and pharmacovigilance systems support readiness, with FDA 15-day expedited reporting for serious unexpected adverse events.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePre-approval pricing \u0026amp; payer dossiers\u003c\/li\u003e\n\u003cli\u003eTargeted specialty field force\u003c\/li\u003e\n\u003cli\u003ePatient hub models for initiation\u003c\/li\u003e\n\u003cli\u003eSupply chain + PV (FDA 15-day reporting)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase 2\/3 NASH\/SHTG trials, multi-kg GMP scale, 2-3 CDMOs, PDUFA 10m \u0026amp; 7y orphan\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore activities: running Phase 2\/3 NASH\/SHTG trials (100s–1,000+ pts) with centralized histology\/biomarkers, patient\/site management and safety monitoring. Scaling BIO89-100 process development for multi-kg GMP batches and tech transfer to 2–3 CDMOs. Regulatory submissions and payer\/launch prep align to FDA timelines (PDUFA 10m, priority 6m) and orphan exclusivity (7y).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial size\u003c\/td\u003e\n\u003ctd\u003e100s–1,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP batch scale\u003c\/td\u003e\n\u003ctd\u003emulti-kg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMOs\u003c\/td\u003e\n\u003ctd\u003e2–3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePDUFA\u003c\/td\u003e\n\u003ctd\u003e10 months (6m priority)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan exclusivity\u003c\/td\u003e\n\u003ctd\u003e7 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThis preview of the 89bio Business Model Canvas is the actual deliverable, not a mockup. When you purchase, you’ll receive this very document—complete, editable, and formatted exactly as shown. The file includes all sections and is ready for download in Word and Excel for immediate use. No surprises, just the same professional canvas you see here.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePegozafermin IP Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePegozafermin IP includes composition, formulation and method-of-use patents that underpin exclusivity; standard patent terms run up to 20 years from filing, supporting pricing power and partnership value. Freedom-to-operate analyses have been performed to reduce litigation risk and guide commercialization. Active lifecycle management plans—patent term adjustments, secondary filings and formulation improvements—aim to extend the franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical and Regulatory Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical-stage, NASDAQ-listed 89bio (ETNB) leverages experienced hepatology, metabolism and biologics teams to drive execution; regulatory experts manage global approval pathways; biostatistics and data management ensure rigorous, reproducible analyses for clinical-readout credibility; medical affairs translates evidence into practice and supports uptake across investigators and payers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Know-how\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcess development and validated analytical methods ensure consistent product quality and batch-to-batch comparability, while relationships with qualified CDMOs provide scalable, flexible capacity compliant with FDA and EMA GMP standards; robust documentation and QA\/QC systems support regulatory submissions, and integrated supply forecasting aligns production with clinical trial enrollment and projected launch timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKOL and Site Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKOL and site networks accelerate enrollment at 89bio by leveraging trusted investigator relationships and established referral pathways, while sites with on-site biopsy and advanced imaging capabilities strengthen histologic and imaging endpoints. Investigator advocacy has supported guideline recognition efforts for NASH therapies. Global site distribution diversifies patient demographics and reduces site-level bias.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrusted KOLs expedite enrollment\u003c\/li\u003e\n\u003cli\u003eBiopsy\/imaging sites enhance data robustness\u003c\/li\u003e\n\u003cli\u003eInvestigator advocacy aids guideline inclusion\u003c\/li\u003e\n\u003cli\u003eGlobal reach diversifies patient demographics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e89bio's financial capital centers on cash reserves and access to equity and non-dilutive funding to advance GLP-1\/FGF21 clinical programs, with milestone-based collaborations (licensing and co-development) commonly used to extend runway.\u003c\/p\u003e\n\u003cp\u003ePrudent burn management prioritizes pivotal trials and manufacturing scale-up, while active investor relations and regular SEC disclosures support continued capital access and investor confidence.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ecash reserves and equity\/non-dilutive funding\u003c\/li\u003e\n\u003cli\u003emilestone-based partnerships extend runway\u003c\/li\u003e\n\u003cli\u003efocused burn management sustains key programs\u003c\/li\u003e\n\u003cli\u003einvestor relations enable ongoing capital access\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust IP, expert hepatology team, GMP CDMOs and KOL networks fuel clinical progress into 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey resources center on Pegozafermin IP (composition, formulation, method-of-use patents with standard 20-year terms) and experienced hepatology\/biologics teams driving development and regulatory strategy. GMP-compliant CDMO partners and validated analytics enable scalable manufacturing and regulatory filings. KOL\/site networks and cash plus milestone partnerships underpin enrollment and runway into 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003e2024 status\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP term\u003c\/td\u003e\n\u003ctd\u003eup to 20 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eListing\u003c\/td\u003e\n\u003ctd\u003eNASDAQ ETNB (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRunway\u003c\/td\u003e\n\u003ctd\u003esupported by cash + milestone deals into 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransformative NASH Option\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePegozafermin, an FGF21 analog, demonstrated in 2023–24 clinical data mean liver fat reductions approaching 50% with accompanying NASH histology improvements, positioning it as a transformative option. Weekly dosing may boost adherence versus more burdensome regimens. Signals of fibrosis improvement address progression risk. Targets a large unmet cohort—no FDA‑approved NASH therapies as of 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSHTG Triglyceride Reduction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEngineered FGF21 biology may deliver substantial TG lowering in SHTG with rapid onset often within 4 weeks, offering cardiometabolic benefits that could lower pancreatitis risk; this complements statins (typical TG reductions 10–30%) and prescription omega‑3s (20–50% reduction), broadening combination utility and commercial reach in a market where SHTG prevalence and high-cost pancreatitis admissions drive unmet need.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMetabolic Comorbidity Benefits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImprovements in insulin sensitivity and lipids can reduce systemic cardiometabolic risk linked to 17.9 million annual cardiovascular deaths (WHO) and 537 million people with diabetes (IDF 2021). A holistic cardiometabolic profile differentiates from liver-only agents by targeting drivers of morbidity. Biomarker-driven positioning enables precision use in defined patient subsets. May complement GLP-1 regimens to enhance metabolic outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-Centered Dosing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOptimized dosing and administration increase usability by simplifying patient steps and supporting adherence through intuitive injection profiles and patient support services that reduce treatment burden.\u003c\/p\u003e\n\u003cp\u003eClear titration and monitoring pathways provide clinicians with standardized algorithms and remote-monitoring options to minimize dose adjustments and clinic visits.\u003c\/p\u003e\n\u003cp\u003eDesign aligns with specialty clinic workflows to streamline training, billing, and scheduling for efficient integration.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003epatient-centered dosing\u003c\/li\u003e\n\u003cli\u003ereduced administration burden\u003c\/li\u003e\n\u003cli\u003eclinician-friendly titration\u003c\/li\u003e\n\u003cli\u003eclinic workflow fit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Evidence and Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWell-designed randomized trials and complementary real-world studies underpin confidence in 89bio therapies, with HEOR analyses demonstrating value propositions to payers and health systems and informing pricing and reimbursement strategies.\u003c\/p\u003e\n\u003cp\u003eCompanion education programs drive appropriate use and adherence, while a firm commitment to safety and active pharmacovigilance sustains clinician and patient trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eEvidence-led trials + RWE\u003c\/li\u003e\n\u003cli\u003eHEOR to payers\/systems\u003c\/li\u003e\n\u003cli\u003eCompanion education for appropriate use\u003c\/li\u003e\n\u003cli\u003eOngoing safety \u0026amp; pharmacovigilance\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\u003c\/h3\u003e\n\u003cp\u003eEngineered FGF21 halves liver fat (~50%), weekly dosing, TG fall in ~4 weeks\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePegozafermin showed mean liver fat reductions ~50% with NASH histology improvement; weekly dosing supports adherence and fibrosis signals address progression risk; engineered FGF21 delivers rapid TG lowering in SHTG often within 4 weeks; targets large unmet need with no FDA‑approved NASH therapies as of 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiver fat reduction\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosing\u003c\/td\u003e\n\u003ctd\u003eWeekly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnset (TG)\u003c\/td\u003e\n\u003ctd\u003e~4 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory landscape\u003c\/td\u003e\n\u003ctd\u003eNo FDA NASH approvals (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFocused interactions target hepatologists, endocrinologists and lipidologists treating NAFLD\/NASH, a continuum affecting ~25% of adults globally with NASH prevalence ~3–5% in adults. Peer-to-peer programs and advisory boards leverage clinical insights and guideline shifts. Responsive MSL support addresses complex cases and triages real-world evidence. Continuous education updates align with evolving 2024 clinical data and payer criteria.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Support Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatient Support Services streamline onboarding, benefits verification, and copay assistance to reduce treatment initiation friction; 2024 IQVIA data show PSPs can boost medication adherence by about 20%. Ongoing adherence programs and automated reminders sustain outcomes, nurse hotlines answer administration questions, and multilingual resources improve access for diverse patient populations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayer Collaboration: value dossiers and outcomes contracts align incentives between 89bio and payers, supported by 2024 CMS guidance encouraging value-based arrangements; medical policy input shapes appropriate coverage criteria and prior authorization frameworks. Data-sharing pilots with select payers validate real-world effectiveness and safety, while transparent pricing and utilization management programs build payer trust and improve uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Touchpoints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDigital touchpoints — provider portals, e-learning, and virtual detailing — extend 89bio’s reach to clinicians and HCPs, supporting scalable engagement; CRM-driven communications personalize outreach (CRM market \u0026gt;70 billion USD in 2024) and boost targeted conversion; real-time logistics tracking reduces delivery failures and improves reliability; closed feedback loops feed continuous improvement and product-market fit.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProvider portals: scale access\u003c\/li\u003e\n\u003cli\u003eE-learning: clinician retention\u003c\/li\u003e\n\u003cli\u003eVirtual detailing: remote reach\u003c\/li\u003e\n\u003cli\u003eCRM-driven: personalized communications\u003c\/li\u003e\n\u003cli\u003eReal-time tracking: reliability\u003c\/li\u003e\n\u003cli\u003eFeedback loops: continuous improvement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Community Building\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupport for registries and investigator-initiated studies builds clinician advocacy by generating real-world evidence and enabling patient-level follow-up; congress symposia disseminate those findings to specialist audiences; guideline and pathway input amplifies uptake into practice; CME partnerships translate evidence into measurable improvements in standard of care.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegistries: real-world evidence drives advocacy\u003c\/li\u003e\n\u003cli\u003eSymposia: rapid dissemination at congresses\u003c\/li\u003e\n\u003cli\u003eGuidelines: pathway influence increases adoption\u003c\/li\u003e\n\u003cli\u003eCME: elevates clinician practice and standards\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHCP-targeted CRM + PSPs drive NASH care adoption; \u003cstrong\u003e~20%\u003c\/strong\u003e adherence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTargeted HCP engagement (hepatologists, endocrinologists, lipidologists) aligns with NAFLD ~25% adult prevalence and NASH ~3–5% (adults). Peer-to-peer programs, MSL triage and CME amplify adoption; PSPs (IQVIA 2024) raise adherence ~20%. Payer value dossiers and CMS 2024 guidance enable outcomes contracts; CRM-driven digital channels (CRM market \u0026gt;70B USD in 2024) scale personalized outreach.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/Fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNAFLD prevalence\u003c\/td\u003e\n\u003ctd\u003e~25% adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNASH prevalence\u003c\/td\u003e\n\u003ctd\u003e~3–5% adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePSP impact (IQVIA)\u003c\/td\u003e\n\u003ctd\u003e+20% adherence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRM market\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70B USD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTargeted specialty reps focus on high-value prescribers in liver and lipid clinics, prioritizing centers treating the ~25% of adults with fatty liver disease. Data-driven territory design uses prescribing and referral analytics to concentrate effort and improve call efficiency. Close coordination with MSLs delivers scientific depth at HCP meetings. Robust compliance frameworks govern all promotional and field interactions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDistribution through specialty pharmacies enables prior authorization support and validated cold-chain handling, critical as specialty medicines represent roughly half of US drug spend per IQVIA 2024; embedded hub services streamline fulfillment and monthly refills, lowering abandonment rates by ~20–30%. Integrated data feeds power adherence analytics, enabling interventions that can raise persistence by ~10–20%. Targeted patient counseling from SPs further improves long-term adherence and outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and IDN Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAccess via formularies and P\u0026amp;T committees drives institutional use across about 6,000 US hospitals, with care pathways embedding initiation and monitoring to standardize outcomes. Health system contracts and bundled payments optimize economics and enable predictable net prices. Protocols support smooth inpatient-to-outpatient transitions and reduce readmissions by aligning pharmacy, case management, and ambulatory teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and Remote Detailing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDigital and remote detailing extends 89bios coverage at lower cost through virtual engagements, with on-demand content tailored for busy specialists; e-consent and e-sampling streamline trial enrollment and market access while metrics drive content optimization and ROI monitoring.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVirtual scale: broader coverage, lower delivery cost\u003c\/li\u003e\n\u003cli\u003eOn-demand: fits specialist schedules\u003c\/li\u003e\n\u003cli\u003eE-consent\/e-sample: faster trials\/access\u003c\/li\u003e\n\u003cli\u003eMetrics: continuous content optimization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical and Scientific Congresses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedical and scientific congresses build awareness and credibility through presentations, with ASCO 2024 reporting about 30,000 attendees, while booths and symposia capture high-value leads for clinical-stage assets. KOL meetups enable deep dives on mechanistic and clinical data. Timely post-conference follow-up converts interest into adoption and trial referrals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePresentations: credibility, broad reach (ASCO 2024 ~30,000)\u003c\/li\u003e\n\u003cli\u003eBooths\/symposia: lead capture\u003c\/li\u003e\n\u003cli\u003eKOL meetups: deep data review\u003c\/li\u003e\n\u003cli\u003eFollow-up: converts interest to adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultichannel liver\/lipid model: reps\/MSLs + hubs cut abandonment \u003cstrong\u003e20-30%\u003c\/strong\u003e and boost persistence \u003cstrong\u003e10-20%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMultichannel model: targeted specialty reps + MSLs focus on liver\/lipid prescribers (25% adults with fatty liver), specialty pharmacies\/hub lower abandonment 20–30% and boost persistence 10–20%; formularies, P\u0026amp;T and 6,000 hospitals embed care pathways; digital detailing and congresses (ASCO 2024 ~30,000) scale reach cost-effectively.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty reps\/MSLs\u003c\/td\u003e\n\u003ctd\u003e25% fatty liver prevalence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacy\/hub\u003c\/td\u003e\n\u003ctd\u003eAbandonment −20–30% \/ Persistence +10–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/P\u0026amp;T\u003c\/td\u003e\n\u003ctd\u003e~6,000 US hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCongress\/digital\u003c\/td\u003e\n\u003ctd\u003eASCO 2024 ~30,000 attendees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNASH Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHepatologists managing biopsy-confirmed NASH with fibrosis (NASH emerging from global NAFLD prevalence ~25%) prioritize therapies with demonstrated histologic benefit and strong safety profiles. They demand unambiguous dosing and monitoring algorithms to manage fibrosis progression and comorbidities. These specialists significantly shape guideline updates and downstream referral pathways, influencing payer and provider adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLipid and Endocrine Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEndocrinologists and lipidologists treating severe hypertriglyceridemia (≈1.7% US prevalence for TG ≥500 mg\/dL) and metabolic syndrome (≈34% of US adults) demand potent triglyceride lowering plus broad metabolic benefits. Clinics prioritize therapies that reduce pancreatitis risk while simplifying polypharmacy and avoiding drug interactions. Adherence-friendly once-daily or infrequent dosing and clear monitoring improve outcomes and clinic uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Health Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntegrated Health Systems, including IDNs and ACOs, prioritize total cost of care and demand robust evidence of reduced hospitalizations and adverse events; they favor streamlined access and patient services and increasingly negotiate outcomes-based agreements—by 2024, industry estimates show over 40% of US healthcare payments tied to value-based arrangements, driving willingness to reimburse for demonstrated event reductions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and PBMs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePayers and PBMs—commercial, Medicare (≈50 million Part D enrollees in 2024), and Medicaid (≈82 million enrollees in 2024)—prioritize robust cost-effectiveness and budget impact analyses for specialty assets, require utilization management criteria tied to standard-of-care, and press for predictable pricing and real-world outcomes; PBMs (top three ≈80% market share in 2024) gatekeep formulary access and contract terms.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCost-effectiveness: ICER thresholds, budget impact modeling\u003c\/li\u003e\n\u003cli\u003eUtilization: step edits, prior authorization, specialty pharmacy carve-outs\u003c\/li\u003e\n\u003cli\u003ePricing demands: predictable net price and outcomes-linked rebates\u003c\/li\u003e\n\u003cli\u003eScale: Medicare\/Medicaid and commercial coverage decisions drive uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients and Caregivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdults with NASH (NAFLD affects ~25% of adults globally) and SHTG (US prevalence ~1.7%) face limited treatment options and seek meaningful clinical gains with manageable side effects. They need clear education, copay assistance and simple, adherence-friendly therapy plans to improve outcomes. Caregivers prioritize quality-of-life gains and predictable side-effect profiles.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePopulation: NASH\/NAFLD ~25% global adults; SHTG ~1.7% US\u003c\/li\u003e\n\u003cli\u003eNeeds: efficacy with low side effects\u003c\/li\u003e\n\u003cli\u003eSupport: education, financial aid\u003c\/li\u003e\n\u003cli\u003eDelivery: easy-to-follow regimens\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialists, payers, patients demand histologic benefit, TG drop; NAFLD \u003cstrong\u003e25%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHepatologists, endocrinologists\/lipidologists, integrated systems, payers\/PBMs and patients\/caregivers drive 89bio adoption—each demands clear histologic benefit, triglyceride reduction, cost-effectiveness, and adherence-friendly regimens. 2024 data: NAFLD ~25% global adults; SHTG ~1.7% US; Medicare Part D ~50M; Medicaid ~82M enrollees; top-3 PBMs ~80% market share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003cth\u003eKey needs\u003c\/th\u003e\n\u003cth\u003e2024 stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHepatologists\u003c\/td\u003e\n\u003ctd\u003eSpecialists\u003c\/td\u003e\n\u003ctd\u003eHistologic benefit, safety\u003c\/td\u003e\n\u003ctd\u003eNAFLD ~25% global\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEndocrinologists\u003c\/td\u003e\n\u003ctd\u003eClinics\u003c\/td\u003e\n\u003ctd\u003eTG lowering, pancreatitis risk\u003c\/td\u003e\n\u003ctd\u003eSHTG ~1.7% US\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\/PBMs\u003c\/td\u003e\n\u003ctd\u003e~All\u003c\/td\u003e\n\u003ctd\u003eCost-effectiveness, outcomes\u003c\/td\u003e\n\u003ctd\u003eTop-3 PBMs ~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDNs\/ACOs\u003c\/td\u003e\n\u003ctd\u003eSystems\u003c\/td\u003e\n\u003ctd\u003eLower total cost, value deals\u003c\/td\u003e\n\u003ctd\u003e~40% value-based payments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003ePopulation\u003c\/td\u003e\n\u003ctd\u003eAccess, affordability, adherence\u003c\/td\u003e\n\u003ctd\u003eMedicare Part D ~50M; Medicaid ~82M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and Clinical Trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMajor R\u0026amp;D spend for 89bio centers on Phase 2\/3 trials—industry 2024 averages: Phase 2 roughly $30–50M and Phase 3 $100–300M—driven by site activation and monitoring costs. Biomarker assays and advanced imaging add an estimated $1–5k per patient. Data management and biostatistics typically consume 10–15% of the trial budget. Continuous safety oversight and DSMBs represent multi-hundred-thousand to low-single-million dollar line items per trial.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and CMC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcess development, GMP batches and validation runs drive high fixed costs—industry 2024 benchmarks show a clinical-scale biologics GMP batch costs $0.5–3M and validation campaigns add 1–2 batches (total $1–6M). Analytical testing and stability programs typically consume 5–10% of CMC spend. Tech-transfer and CDMO capacity reservations require 6–24 month lead times and pre-booking fees often 5–15% of manufacturing budgets; specialized cold-chain logistics add ~10% to supply costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Quality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSubmission prep, agency fees and regulatory consulting form a major fixed cost; FDA PDUFA application fees were approximately $3.2 million in FY2024 and specialist consults often run into the low six figures per program. Pharmacovigilance systems and post‑market commitments add recurring costs—industry estimates place outsourced PV oversight at several hundred thousand to low millions annually. GxP audits, quality management, documentation and compliance training (e‑learning ~ $200–$500 per employee\/year) round out ongoing quality spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial and Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003e89bio allocates commercial and access spend across field force, medical affairs, and targeted marketing to drive specialty uptake; patient support and hub operations sustain adherence and reimbursement navigation; market access and HEOR studies fund formulary positioning and cost-effectiveness evidence; congresses and educational initiatives maintain KOL engagement and guideline influence.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField force\/medical affairs: frontline access\u003c\/li\u003e\n\u003cli\u003ePatient support\/hub: adherence \u0026amp; reimbursement\u003c\/li\u003e\n\u003cli\u003eHEOR\/market access: formulary \u0026amp; value dossiers\u003c\/li\u003e\n\u003cli\u003eCongresses\/education: KOLs \u0026amp; guideline presence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eG\u0026amp;A and Corporate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eG\u0026amp;A and corporate costs fund leadership, legal, finance and facilities that enable 89bio’s clinical and operational programs.\u003c\/p\u003e\n\u003cp\u003eIT infrastructure and cybersecurity spending secure clinical data and support remote collaboration and regulatory submissions.\u003c\/p\u003e\n\u003cp\u003eInsurance, IP prosecution, investor relations and public company costs (89bio traded on NASDAQ as ETNB in 2024) drive recurring legal, filing and compliance expenses.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLeadership, legal, finance, facilities\u003c\/li\u003e\n\u003cli\u003eIT infrastructure \u0026amp; cybersecurity\u003c\/li\u003e\n\u003cli\u003eInsurance \u0026amp; IP prosecution\u003c\/li\u003e\n\u003cli\u003eInvestor relations \u0026amp; public company (NASDAQ: ETNB, 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical costs: Phase 2 \u003cstrong\u003e$30–50M\u003c\/strong\u003e, Phase 3 \u003cstrong\u003e$100–300M\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMajor costs: Phase 2\/3 R\u0026amp;D ($30–50M; $100–300M), biomarker assays $1–5k\/patient, data\/statistics 10–15% of trial spend. CMC\/GMP batches $0.5–3M each, validation $1–6M; CDMO pre-booking 5–15%. Regulatory fees ~ $3.2M PDUFA (2024), PV $0.2–2M\/year. G\u0026amp;A, IT, insurance, IR (NASDAQ: ETNB, 2024) are recurring overheads.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003e2024 Benchmark\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003ctd\u003e$30–50M\u003c\/td\u003e\n\u003ctd\u003esite\/monitoring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3\u003c\/td\u003e\n\u003ctd\u003e$100–300M\u003c\/td\u003e\n\u003ctd\u003elarger scope\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePDUFA\u003c\/td\u003e\n\u003ctd\u003e$3.2M\u003c\/td\u003e\n\u003ctd\u003eFDA fee\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNet sales of pegozafermin upon approval would target NASH and SHTG populations, with NASH affecting roughly 3–5% of U.S. adults (millions) and SHTG (TG ≥500 mg\/dL) estimated at ~1.7% of adults. Pricing is expected to reflect demonstrated clinical value and unmet need for disease-modifying therapies. Specialty pharmacy distribution and patient-support services will drive capture and adherence. Geographic expansion into EU and Asia markets scales addressable revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestones and Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMilestones and upfronts from licensing or co-development deals provide 89bio with non-dilutive cash to advance efruxifermin and other pipeline programs in 2024. Sales-based royalties from partners in selected regions create ongoing revenue streams tied to commercial performance. Co-promotion fees where applicable supplement partner payments. The deal structures prioritize milestone receipts and royalties to fund pipeline advancement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutcomes-Based Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOutcomes-based contracts with payers tie 89bio payments to real-world metrics such as fibrosis regression or MELD improvement, aligning shared-risk to improve affordability and access; robust data infrastructure—electronic registries and claims linkages—enables measurement and verification, reducing payer uncertainty and can materially accelerate formulary adoption and patient uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLifecycle Indication Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e89bio (NASDAQ: ETNB) in 2024 can generate revenue by pursuing additional cardiometabolic indications, turning a single-asset program into multiple indication streams.\u003c\/p\u003e\n\u003cp\u003eLabel expansions materially increase eligible patient populations, dosing or formulation improvements sustain longer-term uptake, and stepwise geographic approvals layer on growth across markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIndication expansion: diversifies revenue per approved use\u003c\/li\u003e\n\u003cli\u003eLabel growth: increases addressable population size\u003c\/li\u003e\n\u003cli\u003eFormulation\/dosing: boosts persistence and repeat sales\u003c\/li\u003e\n\u003cli\u003eGeographic approvals: phases market penetration and revenue timing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrants and Non-dilutive Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e89bio leverages government and foundation grants—with NIH funding at about $48B in 2024—and targeted awards (SBIR\/STTR ~ $1.3B) to support trials, while US tax incentives like the 25% Orphan Drug Tax Credit and the 14% alternative R\u0026amp;D tax credit pathway materially reduce net spend and cash burn.\u003c\/p\u003e\n\u003cp\u003eCollaborative funding for registries and real-world evidence partnerships share costs and provide a low-dilution bridge to commercialization, preserving equity ahead of larger financing rounds.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNIH 2024 funding ~ $48B\u003c\/li\u003e\n\u003cli\u003eSBIR\/STTR 2024 ~ $1.3B\u003c\/li\u003e\n\u003cli\u003eOrphan Drug Tax Credit 25% (2024)\u003c\/li\u003e\n\u003cli\u003eAlt. R\u0026amp;D tax credit ~14%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNASH and SHTG launch: specialty pricing, licensing upfronts, outcomes-based payer deals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePegozafermin revenue targets NASH (3–5% US adults ≈7.8–13.0M) and SHTG (~1.7% ≈4.4M), priced to reflect disease-modifying value and specialty distribution. Licensing upfronts, milestones and royalties provide non-dilutive cash; outcomes-based payer contracts link payment to fibrosis\/MELD results. Geographic and indication expansion plus grants\/tax credits de-risk commercialization and extend lifetime revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS adult pop\u003c\/td\u003e\n\u003ctd\u003e≈260M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNASH prev.\u003c\/td\u003e\n\u003ctd\u003e3–5% (7.8–13.0M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSHTG prev.\u003c\/td\u003e\n\u003ctd\u003e1.7% (≈4.4M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH funding\u003c\/td\u003e\n\u003ctd\u003e$48B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan credit\u003c\/td\u003e\n\u003ctd\u003e25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097834262876,"sku":"89bio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/89bio-business-model-canvas.png?v=1781787170","url":"https:\/\/pestel-analysis.com\/products\/89bio-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}